Novo Nordisk tumbles as next-gen obesity drug data disappoints investors

Novo Nordisk A/S (NVO) is down 15.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to underwhelming clinical results for Novo Nordisk’s next-generation obesity candidate, CagriSema, which investors had viewed as an important product to defend share against intensifying competition. The data suggested the therapy did not match a leading rival on weight-loss outcomes in a head-to-head study, pressuring expectations for future growth in the obesity franchise.

Details:

Novo Nordisk released results showing CagriSema produced about 23% average weight loss over 84 weeks in a trial, which investors viewed as less competitive versus a key rival therapy’s reported outcomes.

The head-to-head study design and outcome raised concerns that CagriSema may be less differentiated than hoped, potentially limiting its ability to regain momentum in the obesity market.

Novo Nordisk has previously stated it submitted CagriSema for U.S. regulatory review in late 2025, with a decision expected later in 2026, so today’s reaction likely reflects repricing of the drug’s commercial outlook.

This move also fits into broader investor sensitivity around obesity-drug competition and pricing dynamics, where even modest efficacy gaps can shift market-share assumptions.

Sources:

Financial Times, The Guardian, Investor’s Business Daily

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NVO Hedge Fund Activity

We have seen 596 institutional investors add shares of $NVO stock to their portfolio, and 968 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 10,005,216 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $555,189,435
CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
GOLDMAN SACHS GROUP INC added 4,270,420 shares (+63.6%) to their portfolio in Q4 2025, for an estimated $217,278,969
FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$NVO Congressional Stock Trading

Members of Congress have traded $NVO stock 6 times in the past 6 months. Of those trades, 4 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 10/30, 09/11 and 2 sales worth up to $30,000 on 10/31, 10/30.
REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 10/15, 08/28 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$NVO Analyst Ratings

Wall Street analysts have issued reports on $NVO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.

Here are some recent analyst ratings:

Goldman Sachs issued a "Buy" rating on 11/28/2025
Jefferies issued a "Underperform" rating on 10/27/2025
Morgan Stanley issued a "Underweight" rating on 09/29/2025
Berenberg issued a "Buy" rating on 09/17/2025

To track analyst ratings and price targets for $NVO, check out Quiver Quantitative's $NVO forecast page.

$NVO Price Targets

Multiple analysts have issued price targets for $NVO recently. We have seen 5 analysts offer price targets for $NVO in the last 6 months, with a median target of $54.0.

Here are some recent targets:

An analyst from CICC set a target price of $73.5 on 01/09/2026
James Quigley from Goldman Sachs set a target price of $54.0 on 11/28/2025
Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
Rajesh Kumar from HSBC set a target price of $70.0 on 10/02/2025
Thibault Boutherin from Morgan Stanley set a target price of $47.0 on 09/29/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.